Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dasotraline Pediatric ADHD Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02428088
Recruitment Status : Completed
First Posted : April 28, 2015
Last Update Posted : July 2, 2017
Sponsor:
Information provided by (Responsible Party):
Sunovion

Brief Summary:
This is a 6 week efficacy and safety study of Dasotraline in subjects 6 to 12 years old with ADHD.

Condition or disease Intervention/treatment Phase
Attention Deficit Hyperactivity Disorder Drug: Dasotraline Drug: Placebo Comparator Phase 2 Phase 3

Detailed Description:
This is a randomized, double blind, multicenter, placebo-controlled, parallel group, outpatient study evaluating the efficacy and safety of dasotraline in subjects 6 to 12 years of age with ADHD using 2 doses of dasotraline (2 mg/day and 4 mg/day) versus placebo over a 6 week treatment period. The study will consist of screening, treatment, and end of study visits.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 330 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 6-week, Randomized, Double-Blind, Multicenter, Placebo-Controlled, Parallel-group Efficacy and Safety Study of Dasotraline Versus Placebo in Subjects 6 to 12 Years of Age With Attention Deficit Hyperactivity Disorder (ADHD)
Study Start Date : April 2015
Actual Primary Completion Date : July 2016
Actual Study Completion Date : July 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Dasotraline 2 mg
Dasotraline 2 mg
Drug: Dasotraline
Dasotraline 2 mg once daily
Other Name: SEP-225289

Experimental: Dasotraline 4 mg
Dasotraline 4 mg
Drug: Dasotraline
Dasotraline 4 mg once daily
Other Name: SEP-225289

Placebo Comparator: Placebo
Placebo
Drug: Placebo Comparator
Placebo once daily




Primary Outcome Measures :
  1. Change from baseline at Week 6 in ADHD symptoms as measured by ADHD RS IV HV. [ Time Frame: Baseline, 6 Weeks ]

Secondary Outcome Measures :
  1. Change from baseline in ADHD symptoms as measured by in ADHD RS IV HV at Weeks 1, 2, 3, 4, and 5. [ Time Frame: Baseline, Weeks 1,2,3,4,5 ]
  2. Change from baseline in the inattentiveness and hyperactivity subscales of the ADHD RS IV HV at Weeks 1, 2, 3, 4, 5, and 6. [ Time Frame: Baseline, Weeks 1,2,3,4,5,6 ]
  3. The percentage of responders at Weeks 1, 2, 3, 4, 5, and 6. A responder is defined as a subject with a ≥ 30% improvement in ADHD symptoms compared with baseline as measured by the ADHD RS IV HV. [ Time Frame: Baseline, Weeks 1,2,3,4,5,6 ]
  4. Change from baseline in CGI-S scale at Weeks 1, 2, 3, 4, 5, and 6. [ Time Frame: Baseline, Weeks 1,2,3,4,5,6 ]
  5. Change from baseline in Conners 3 P total score and subscale scores (Oppositional, Cognitive problems, Hyperactivity, and ADHD Index) at Weeks 1, 2, 3, 4, 5, and 6. [ Time Frame: Baseline, Weeks 1,2,3,4,5,6 ]
  6. Change from baseline in Conners 3 T total score at Weeks 3 and 6. [ Time Frame: Baseline, Weeks 3, 6 ]
  7. Change from baseline in WPREMB R total score and subscores at Weeks 1, 2, 3, 4, 5, and 6. [ Time Frame: Baseline, Weeks 1,2,3,4,5,6 ]
  8. The incidence of overall AEs, serious AEs (SAEs), and AEs (or SAEs) leading to discontinuations. [ Time Frame: Baseline, 6 Weeks ]
  9. Absolute values and change from baseline in clinical laboratory evaluations (serum chemistry). [ Time Frame: Baseline, 6 Weeks ]
  10. Absolute values and change from baseline in clinical laboratory evaluations (hematology). [ Time Frame: Baseline, 6 Weeks ]
  11. Absolute values and change from baseline in clinical laboratory evaluations (lipid panel). [ Time Frame: Baseline, 6 Weeks ]
  12. Absolute values and change from baseline in clinical laboratory evaluations (thyroid panel). [ Time Frame: Baseline, 6 Weeks ]
  13. Absolute values and change from baseline in clinical laboratory evaluations (sex hormones). [ Time Frame: Baseline, 6 Weeks ]
  14. Absolute values and change from baseline in clinical laboratory evaluations (urinalysis). [ Time Frame: Baseline, 6 Weeks ]
  15. Absolute values and changes from baseline in 12 lead ECGs. [ Time Frame: Baseline, 6 Weeks ]
  16. Absolute values and changes from baseline in vital signs. [ Time Frame: Baseline, 6 Weeks ]
  17. Absolute values and changes from baseline in body weights. [ Time Frame: Baseline, 6 Weeks ]
  18. Change from baseline in CSHQ total score and 8 subscale scores (bedtime resistance, sleep onset delay, sleep duration, sleep anxiety, night wakings, parasomnias, sleep disordered breathing, and daytime sleepiness) at Weeks 1, 2, 3, 4, 5, and 6. [ Time Frame: Baseline, Weeks 1,2,3,4,5,6 ]
  19. Change from baseline in Tanner staging at Week 6. [ Time Frame: 6 Weeks ]
  20. Frequency of suicidal ideation and suicidal behavior as assessed by the C SSRS. [ Time Frame: 6 Weeks ]
  21. Severity of suicidal ideation and suicidal behavior as assessed by the C SSRS. [ Time Frame: 6 Weeks ]
  22. Dasotraline plasma concentration for PK at Weeks 2, 4, and 6. [ Time Frame: Baseline, Weeks 2,4,6 ]
  23. Change from baseline in DHPG concentration at Weeks 2, 4, and 6. [ Time Frame: Baseline, Weeks 2,4,6 ]
  24. Change from baseline in NE concentration at Weeks 2, 4, and 6. [ Time Frame: Baseline, Weeks 2,4,6 ]
  25. Change from baseline in WFIRS P total score and 6 domain scores (family, learning and school, life skills, child's self-concept, social activities and risky activities) at Week 3 and 6. [ Time Frame: Baseline, Weeks 3,6 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   6 Years to 12 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject's parent/legal guardian must give written informed consent, including privacy authorization, prior to study participation. The subject will complete an informed assent prior to study participation.
  • Subject and the subject's parent/legal guardian must be judged by the investigator to be willing and able to comply with the study procedures and visit schedules.
  • Subject, male or female, must be between 6 and 12 years of age, inclusive, at the time of consent/assent and at Baseline.
  • Subject meets Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM 5) criteria for a primary diagnosis of ADHD (inattentive, hyperactive, or combined presentation) at screening established by a comprehensive psychiatric evaluation that reviews DSM 5 criteria is confirmed using the K-SADS-PL at Screening.
  • Subject has an ADHD RS IV HV score of ≥ 28.
  • Subject has a CGI S score of ≥ 4.
  • Subject, if female, must not be pregnant or breastfeeding, and if ≥ 8 years of age must have a negative pregnancy test.
  • Female subject:

    • must be unable to become pregnant (eg, premenarchal, surgically sterile, etc);

OR

• practice true abstinence (consistent with lifestyle) and must agree to remain abstinent from signing informed consent/assent to at least 14 days after the last dose of study drug has been taken;

OR

• is sexually active and willing to use a medically effective method of birth control (see Appendix VII) from signing informed consent/assent to at least 14 days after the last dose of study drug has been taken.

  • Male subject must be willing to remain sexually abstinent (consistent with lifestyle) or be using an effective method of birth control from signing informed consent/assent to at least 14 days after the last dose of study drug has been taken.
  • Subject must be in general good health (defined as the absence of any clinically relevant abnormalities as determined by the Investigator) based on screening physical and neurological examinations, vital signs, medical history, and clinical laboratory values (hematology, chemistry, and urinalysis). Note: If any of the hematology, chemistry, or urinalysis results are not within the laboratory's reference range, then the subject may be included only if the investigator determines the deviations to be not clinically relevant.
  • Subject weighs at least 21 kg and is within 3rd to 97th percentile for gender specific body-mass-index (BMI)-for-age from the World Health Organization (WHO) growth charts (see Appendices II and IX).
  • Subject's parent/legal guardian must report a history of the subject being able to swallow capsules.
  • Subject and subject's parents/legal guardians must be able to fully comprehend the informed consent/assent form (as applicable), understand all study procedures, and be able to communicate satisfactorily with the Investigator and study coordinator.

Exclusion Criteria:

  • Subject or parent/legal guardian has commitments during the study that would interfere with attending study visits.
  • Subject currently has a diagnosis of asthma that has required daily treatment with bronchodilators or nebulizer treatments in the 30 days prior to screening and/or who may require daily treatments with these agents over the course of the trial. Intermittent use of bronchodilators is not exclusionary. Subjects who have a history of requiring persistent asthma treatment should be discussed wit the medical monitor prior to enrolment.
  • Subject has any clinically significant unstable medical abnormality, chronic disease, or a history of a clinically significant abnormality of the cardiovascular, gastrointestinal, respiratory, hepatic, or renal systems, or a disorder or history of a condition (eg, malabsorption, gastrointestinal surgery) that may interfere with drug absorption, distribution, metabolism, or excretion. Note: Active medical conditions that are minor or well-controlled are not exclusionary if they do not affect risk to the subject or the study results. In cases in which the impact of the condition upon risk to the subject or study results is unclear, the Medical Monitor should be consulted. Any subject with a known cardiovascular disease or condition (even if controlled) must be discussed with the Medical Monitor during screening.
  • Subject has a history or presence of abnormal ECGs, which in the investigator's opinion is clinically significant. Screening site ECGs will be centrally over-read, and eligibility will be determined by the investigator based on the results of the over-read report.
  • Subject has any documented diagnosis of Bipolar I or II Disorder, major depressive disorder, conduct disorder, obsessive-compulsive disorder, disruptive mood dysregulation disorder (DMDD), intellectual disability, any history of psychosis, autism spectrum disorder, Tourette's Syndrome, confirmed genetic disorder with cognitive and/or behavioral disturbances. Note: Subjects with oppositional defiant disorder (ODD) are permitted to enroll in the study as long as ODD is not the primary focus of treatment.
  • Subject has generalized anxiety disorder that has been the primary focus of treatment at any time during the 12 months prior to screening or that required pharmacotherapy any time in the 6 months prior to screening.
  • Subject has failed 2 adequate courses of stimulant or non-stimulant treatment for ADHD, as judged by the investigator.
  • Subject has evidence of any chronic disease of the central nervous system (CNS) such as tumors, inflammation, seizure disorder, vascular disorder, potential CNS related disorders that might occur in childhood (eg, Duchenne Muscular dystrophy, myasthenia gravis, or other neurologic or serious neuromuscular disorders), or history of persistent neurological symptoms attributable to serious head injury. Past history of febrile seizure, drug-induced seizure, or alcohol withdrawal seizure is exclusionary. Subject taking anticonvulsants for seizure control currently or within the past 2 years is not eligible for study participation.
  • Subject has uncontrolled thyroid disorder indicated by free T4, free T3, or thyroid stimulating hormone (TSH) outside the limit of normal for the reference laboratory.
  • Subject answers "yes" to "Suicidal Ideation" item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) for any lifetime history on the C SSRS Children's Lifetime/Recent assessment at screening.
  • Subject has any history of attempted suicide, in the opinion of the investigator.
  • Subject does not tolerate venipuncture or has poor venous access that would cause difficulty for collecting blood samples.
  • Subject has a history of severe allergies to more than 1 class of medications or multiple adverse drug reactions or has a history of allergic reaction or has a known or suspected sensitivity to any substance that is contained in the study drug formulations.
  • Subject has history of intolerance to stimulants.
  • Subject has taken any antipsychotic medication within 8 weeks prior to screening.
  • Subject taking any medication, including health food supplements with purported psychotropic activity (for example, St. John's Wort), must have a minimum washout of 7 days prior to Day 1.
  • Subject taking any antidepressant medication (eg, bupropion, selective serotonin reuptake inhibitor [SSRI]/ serotonin norepinephrine reuptake inhibitor [SNRI], monoamine oxidase [MAO] inhibitor, tricyclic, etc) must have a minimum washout of 7 days prior to Day 1.
  • Subject is currently undergoing Cognitive Behavioral Therapy (CBT) for the treatment of ADHD, has initiated behavioral therapy (including school based interventions) less than 1 month prior to screening, or is receiving behavioral therapy and in the opinion of the investigator will not be able to follow a stable routine for the duration of the study.
  • Subject or subject's family anticipates a move outside the geographic range of investigative site during the study period, or plans extended travel inconsistent with the recommended visit interval during study duration.
  • Subject has a history of, or current malignancy except for non melanomatous skin cancer.
  • Subject has history of positive test for Hepatitis B surface antigen or Hepatitis C antibody and has liver function test results at screening above the upper limit of normal for the reference laboratory.
  • Subject is known to have tested positive for human immunodeficiency virus (HIV).
  • Subject has participated in any investigational study within 90 days prior to screening or is currently participating in another clinical trial.
  • Subject has a history of substance or alcohol use disorder (excluding caffeine) within the 12 months prior to screening, as defined by the DSM 5 criteria, or is currently using tobacco or other nicotine-containing products, or has a positive urine drug screen (UDS) or breath alcohol test at screening. Note: Subjects with a positive UDS may be allowed to continue in the study, provided that the investigator determines that the positive test is as a result of taking prescription medicine(s) as prescribed.
  • Subject requires treatment with any disallowed medications during the study.
  • Subject has experienced significant blood loss within 60 days prior to screening.
  • Subject has previously been enrolled in a clinical trial of dasotraline (SEP 225289).
  • Subject's parent/legal guardian is an investigational site staff member or the relative of an investigational site staff member.
  • Subject is, in the opinion of the Investigator, unsuitable in any other way to participate in this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02428088


  Show 43 Study Locations
Sponsors and Collaborators
Sunovion
Investigators
Layout table for investigator information
Study Director: Dasotraline Medical Director, MD Sunovion

Layout table for additonal information
Responsible Party: Sunovion
ClinicalTrials.gov Identifier: NCT02428088     History of Changes
Other Study ID Numbers: SEP360-202
First Posted: April 28, 2015    Key Record Dates
Last Update Posted: July 2, 2017
Last Verified: June 2017

Additional relevant MeSH terms:
Layout table for MeSH terms
Attention Deficit Disorder with Hyperactivity
Hyperkinesis
Attention Deficit and Disruptive Behavior Disorders
Neurodevelopmental Disorders
Mental Disorders
Dyskinesias
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms